Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea
- 2 June 2014
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 93 (5) , 377-383
Abstract
Background: More than 90% of children with sickle cell anemia (SCA) lose splenic function by the age of 2 yrs. Splenic function may improve with hydroxyurea, but previous studies are conflicting. We prospectively evaluated the effect of hydroxyurea on splenic filtrative function.Methods: Children with SCA enrolled in the Hydroxyurea Study of Long‐Term Effects (HUSTLE‐NCT00305175) underwent clinical evaluations including Tc99m liver–spleen (LS) scans before hydroxyurea initiation and after 3 yrs of treatment to maximum tolerated dose (MTD). LS scans were classified as follows: no uptake, N = 40) was 9.1 yrs, range 2.3–17.0. After 3 yrs of treatment, 13 (33%) had uptake on LS scan. These 13 children were younger (median age 6.0 vs. 10.6 yrs, P = 0.008), had a higher HbF at baseline (mean 10.2% vs. 5.8%, P = 0.004) and after 3 yrs (22.9% vs. 13.9%, P < 0.001), achieved MTD more rapidly (median 288 vs. 358 d, P = 0.021), and were more likely to have baseline splenic uptake (P < 0.001).Conclusions: Hydroxyurea at MTD is associated with preserved or improved splenic filtrative function, with 33% demonstrating LS scan uptake after 3 yrs. Younger age, higher %HbF, and baseline splenic function are associated with a favorable outcome.Keywords
This publication has 29 references indexed in Scilit:
- Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell ProgramPLOS ONE, 2013
- The effect of hydroxcarbamide therapy on survival of children with sickle cell diseaseBritish Journal of Haematology, 2013
- Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaBlood, 2011
- Glomerular hyperfiltration and albuminuria in children with sickle cell anemiaPediatric Nephrology, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damageMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007
- Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccinationThe Journal of Pediatrics, 2003
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Prophylaxis with Oral Penicillin in Children with Sickle Cell AnemiaNew England Journal of Medicine, 1986